{ "article": { "format_version": 5, "presentation": "complete-card", "overview": "Prenatal care combines regular assessment, time-sensitive prevention, explained test results and help between visits. Contact a prenatal service early, review medicines and the folic-acid plan, and ask how results and urgent concerns are handled. A screening result estimates or flags a risk; it does not settle every health question. Severe headache, vision change, chest pain, bleeding or a later drop in movement needs prompt clinical attention. The care team should tailor the plan to your history and circumstances.", "sections": [ { "id": "understanding-prenatal-care", "role": "explanation", "title": "What prenatal care helps you understand", "intro": "Prenatal means before birth; antenatal means the same thing. Care follows both the pregnant person's health and the developing baby's health. An appointment, a preventive treatment, a screening test and an urgent assessment have different jobs. These four familiar situations show why that distinction matters.", "items": [ { "label": "Make early contact so the team can plan the right care", "text": "If you have a positive pregnancy test and feel well, you can still contact a prenatal service now and ask when assessment should begin. WHO describes antenatal care as continuing assessment, prevention, symptom support and education, rather than a visit reserved for illness. Medical history, previous pregnancies and current medicines can change what needs attention first. Ask how pregnancy dates will be established, because test and vaccine windows depend on how far along the pregnancy is. Tell the service about those concerns when booking, even if its first routine appointment is several weeks away. Ask what to do while waiting, who explains results and how to reach help after hours. If care starts later than expected, make contact now; missed time is a reason to prioritize remaining care, not to abandon it.", "source_ids": [ "who-care", "prenatal-care" ] }, { "label": "Review prevention while you are waiting for the first visit", "text": "A prenatal vitamin, a vaccine and a prescription prevent different problems. Folic acid has evidence for reducing particular early brain and spinal-cord defects; it is not a promise that every pregnancy complication is prevented. Tdap helps protect an infant against whooping cough, and its pregnancy timing differs from the seasonal flu vaccine. Bring supplement ingredients and vaccination dates so the team can see what is already covered and what applies next. Do not assume that the word prenatal on a product establishes its contents, or that a previous adult vaccine dose completes every pregnancy recommendation.", "source_ids": [ "folic-clinical", "acog-vaccines" ] }, { "label": "Use urgent assessment when a symptom changes", "text": "A severe headache with vision changes, chest pain, bleeding or a change in the baby's usual movement is a different question from scheduling the next routine checkup. CDC's HEAR HER campaign directs people with maternal warning signs to seek care promptly during pregnancy and up to a year afterward. A clinician may need an examination, blood-pressure measurement or fetal assessment to explain the symptom. A reassuring comment online cannot do those things. State the pregnancy stage or recent delivery and when the change began; emergency symptoms need emergency care rather than a routine appointment or an online reply.", "source_ids": [ "warning-signs" ] }, { "label": "Ask what each test can tell you and what follows the result", "text": "If you are offered blood tests, an ultrasound or genetic testing, the important first question is what each one is checking. Screening identifies a possible problem or estimates a chance; diagnosis investigates or confirms a specific condition. An abnormal initial glucose screen can lead to a longer diagnostic test, while a genetic blood screen can lead to counseling and a different kind of confirmatory test. Ask what a positive, negative or unclear result means and who will contact you. A result is useful when its limits and follow-up are explained, not simply when it appears in a portal.", "source_ids": [ "gdm", "genetic-screening" ] } ] }, { "id": "prevention-with-a-purpose", "role": "findings", "title": "What the prevention findings actually mean", "intro": "Prevention aims to lower a risk before a problem develops. It can be useful without being a guarantee, and its dose, timing and eligible population are part of the finding.", "items": [ { "label": "Cover folic acid before the early development window", "text": "The neural tube is the early structure that becomes the brain and spinal cord. When it does not close completely, neural-tube defects can result; closure occurs very early, often before pregnancy is recognized. In its 2023 evidence-based recommendation, USPSTF recommends a daily supplement containing 400–800 micrograms of folic acid for average-risk people who plan to or could become pregnant, starting at least one month before conception and continuing through the first two to three months. This reduces risk rather than eliminating it. A previous affected pregnancy, relevant family history or medicines that interfere with folic acid falls outside that standard recommendation and needs individual clinical review.", "source_ids": [ "folic-acid" ] }, { "label": "Read the nutrient and amount rather than relying on the brand name", "text": "Folate is vitamin B9; folic acid is a form used in supplements and fortified foods with neural-tube-prevention evidence. A label can show several folate terms, so bring the actual label if the amount is unclear. CDC explains that common MTHFR gene variants do not stop the body processing folic acid; an internet genetics result is not, by itself, a reason to replace the established prevention approach. More products do not automatically mean more protection. Review overlapping vitamins and any higher-risk history with the team rather than selecting extra doses yourself. Starting later cannot turn back an early development window, but it is still worth discussing your current nutrition and care needs.", "source_ids": [ "folic-label", "mthfr", "folic-clinical" ] }, { "label": "Match each vaccine to its pregnancy purpose and timing", "text": "Maternal vaccination can protect the pregnant person and, through antibodies passed before birth, help protect an infant. CDC recommends Tdap in each pregnancy, preferably early in weeks 27–36; a prior adult dose does not replace that pregnancy dose. An inactivated or recombinant flu vaccine is recommended during the relevant season; the live nasal-spray product is different. For eligible pregnancies, maternal RSV prevention uses Abrysvo at 32 weeks 0 days through 36 weeks 6 days, seasonally—September through January in most of the continental US. Other adult RSV products are not interchangeable. Prior maternal RSV vaccination changes the later pregnancy/infant prevention plan. Ask the team to record the product, date and purpose, including any regional seasonal differences.", "source_ids": [ "vaccines" ] }, { "label": "Use the current seasonal vaccine guidance with your care team", "text": "ACOG's 2026 maternal schedule includes COVID-19 vaccination and allows it during any trimester. CDC's newer 2026–2027 clinical considerations recommend a seasonal COVID-19 vaccine for adults and ask patients and clinicians to discuss benefits and risks. Pregnancy increases the risk of severe COVID-19 illness, which is part of that discussion. Older public pages may still describe the previous season, so the date and linked current schedule matter. The practical question is which current product and timing fit your vaccination history and health, including any prior reaction. Reading a page does not establish your individual product eligibility or dose.", "source_ids": [ "acog-vaccines", "covid-current", "covid-pregnancy" ] }, { "label": "Use alcohol prevention without making a prediction about the past", "text": "CDC has not identified a safe amount, time or type of alcohol during pregnancy. Alcohol can reach the developing fetus, and pregnancies do not all respond to exposure in the same way. The prevention recommendation is therefore to avoid alcohol, not to use a relative's healthy child as evidence for a safe allowance. If you drank before knowing you were pregnant, tell the prenatal team what occurred and continue care. That disclosure helps a clinical conversation; it does not let a website predict damage or guarantee reassurance. If avoiding alcohol is difficult, ask the clinician for support promptly rather than trying to manage the concern through shame or concealment.", "source_ids": [ "alcohol" ] }, { "label": "Review medicines by balancing treatment and untreated illness", "text": "A medicine review includes prescriptions, nonprescription products, herbal remedies, dietary supplements and vitamins. CDC emphasizes that stopping a needed medicine can sometimes be more harmful than taking it, while some medicines can pose pregnancy risks. The decision depends on the condition being treated, the actual ingredient and dose, pregnancy timing and available evidence. A natural label supplies none of that comparison. Bring bottles or an accurate list with doses and frequency, and contact the prescribing and prenatal teams before starting or stopping treatment. Gaps in research mean uncertainty needs explanation; they do not mean every exposure is safe or every treatment should be abandoned.", "source_ids": [ "medicines" ] } ] }, { "id": "screening-and-follow-up", "role": "findings", "title": "How the main prenatal assessments work", "intro": "Tests answer specific questions. Understanding the question makes both reassuring and abnormal results easier to use.", "items": [ { "label": "Understand the glucose pathway before interpreting the number", "text": "Gestational diabetes means high blood glucose first diagnosed during pregnancy. Pregnancy can make the body less responsive to insulin, the hormone that helps move glucose out of the blood. USPSTF supports screening in people without known type 1 or type 2 diabetes at 24 weeks or later, commonly 24–28 weeks in US care. In a two-step pathway, a shorter initial glucose challenge is followed by an oral glucose-tolerance test if needed. A one-step pathway uses a diagnostic tolerance test directly. The drink, fasting instructions and number of blood samples depend on the pathway. Ask which test you are having; an abnormal screening value and a diagnosis are different pieces of information.", "source_ids": [ "gdm" ] }, { "label": "Keep blood-pressure assessment separate from aspirin prevention", "text": "Blood pressure is the force of circulating blood against artery walls. Pregnancy-related high blood pressure sometimes accompanies preeclampsia, a disorder that can also involve organ problems or other clinical findings. Monitoring helps the team identify change; aspirin is a separate preventive treatment for selected people at increased risk. USPSTF recommends clinician-prescribed low-dose aspirin after 12 weeks for eligible high-risk pregnancies, with US guidance specifying 81 mg daily. Previous preeclampsia, chronic hypertension and certain other medical histories affect eligibility. The task force's trial synthesis found fewer preeclampsia cases in high-risk groups, not universal protection. Ask whether the criteria fit your history; do not start aspirin from this article, and keep reporting symptoms even if it is prescribed.", "source_ids": [ "blood-pressure", "aspirin" ] }, { "label": "Treat genetic screening as an estimate that may need confirmation", "text": "Cell-free DNA screening, sometimes called NIPT, examines fragments of DNA circulating in the pregnant person's blood, including DNA arising mainly from the placenta. It is a sensitive screen for selected chromosome-number conditions, but it is not a direct diagnostic examination of the fetus. A positive result can be false, and a negative result cannot exclude every genetic or structural condition. SMFM's 2025 guidance, endorsed by ACOG, supports offering common-condition screening with informed counseling and the option to accept or decline testing. Ask what conditions are included and what confirmation is offered after a positive or unclear result. The result should guide a careful discussion, not be treated as an individual prognosis.", "source_ids": [ "genetic-screening", "genetic-detail" ] }, { "label": "Choose the breadth of genetic information deliberately", "text": "Chromosome conditions are not all tested with equal accuracy. Trisomy means an extra copy of a chromosome; a microdeletion is a missing small chromosome segment. The SMFM guidance treats common trisomy screening, sex-chromosome screening and rare microdeletion panels differently. Sex-chromosome screening is an opt-in choice with counseling; routine general-population microdeletion screening is not recommended. More listed conditions can mean more uncertainty and additional testing, rather than a more complete guarantee. Discuss which information you want for care and preparation, what a laboratory actually validates, and how an uncertain or unexpected result would be handled before the sample is sent.", "source_ids": [ "genetic-screening", "genetic-detail" ] }, { "label": "Connect an abnormal glucose result to continuing care", "text": "The purpose of identifying gestational diabetes is to help manage glucose and reduce selected pregnancy risks, not merely attach a label. USPSTF's evidence review found treatment benefits for outcomes including large-for-gestational-age birth and shoulder dystocia, when a baby's shoulder becomes difficult to deliver. A care plan may include nutrition support, checking glucose and medication when indicated; the details belong to your clinical team. Ask who will explain results, how monitoring is reviewed and what follow-up is planned after delivery. A diagnosis should lead to understandable support. A normal test also does not settle unrelated symptoms, blood pressure or later concerns.", "source_ids": [ "gdm" ] } ] }, { "id": "questions-the-field-is-working-through", "role": "perspectives", "title": "Why care approaches can differ", "intro": "These differences concern how to deliver care or interpret a test. They do not turn folic-acid prevention, urgent assessment or all recommended vaccines into optional matters of opinion.", "items": [ { "label": "Discuss a visit schedule that delivers the needed services", "text": "A fixed sequence of frequent office visits and a tailored combination of office and remote care are different ways of arranging services. Michigan researchers working with ACOG describe evidence supporting tailored care for average-risk pregnancies, while high-risk histories may need closer monitoring. The unresolved work includes implementation, access, technology and whether the new models serve different populations equally well. Fewer office visits must still include necessary assessments, tests, prevention and accessible between-visit contact. Ask what each contact accomplishes, what requires an in-person appointment and what would change the schedule. A preference for convenience alone cannot establish that a reduced schedule fits your pregnancy.", "source_ids": [ "prenatal-care", "care-preferences" ] }, { "label": "Compare glucose-testing pathways by outcomes as well as diagnoses", "text": "The one-step and two-step approaches use different thresholds, so they identify different numbers of people as having gestational diabetes. Hillier and colleagues randomized 23,792 pregnancies in two US health systems: 16.5% were diagnosed in the one-step group versus 8.5% in the two-step group, yet measured main pregnancy and infant outcomes did not significantly differ. More diagnoses did not automatically produce better measured outcomes in that trial. Adherence differed between groups, and the result does not establish that testing or treatment is useless. This is a genuine debate about thresholds, benefit and burden within screening. Ask which local protocol is used and what its result requires, rather than judging its quality by how many diagnoses it finds.", "source_ids": [ "gdm-pathways" ] }, { "label": "Ask whether an early glucose test is checking a different risk", "text": "USPSTF's 2021 statement found insufficient evidence to judge routine gestational-diabetes screening before 24 weeks; insufficient evidence is different from evidence that it should never occur. In the 2023 TOBOGM trial, Simmons and colleagues studied 802 women with a risk factor and already-diagnosed early gestational diabetes. Immediate treatment modestly reduced a combined infant-outcome measure, without materially changing pregnancy-related hypertension or neonatal lean body mass. That selected treatment trial does not show that every pregnant person benefits from universal early screening. Testing for previously unrecognized diabetes is also a separate clinical question. Ask why an early test is proposed for you and what action would follow its result.", "source_ids": [ "gdm", "early-gdm" ] }, { "label": "Ask which diagnostic sample best answers a positive genetic screen", "text": "After some positive sex-chromosome screens, clinicians may discuss chorionic villus sampling, which samples placental tissue, or amniocentesis, which samples fluid containing fetal cells. SMFM describes continuing debate because an abnormal chromosome pattern can be present in the placenta without matching the fetus. A placental sample can provide information earlier but sometimes needs further clarification; waiting for a different sample changes the timing of information. The best choice depends on the suspected condition, ultrasound findings and laboratory method. This is a specialist counseling question, not a reason to treat the original blood screen as diagnostic. Ask what each option can confirm and what uncertainty might remain.", "source_ids": [ "genetic-detail" ] } ] }, { "id": "care-in-ordinary-life", "role": "application", "title": "How to make the care plan fit ordinary life", "intro": "Care becomes more usable when its medical purpose and practical support are connected.", "items": [ { "label": "Read weight gain as a clinical trend rather than a personal verdict", "text": "Pregnancy weight includes changes in maternal tissues and fluid as well as the developing baby; a scale cannot separate those components. CDC's ranges, grounded mainly in National Academies guidance, depend on prepregnancy BMI and differ for singleton and twin pregnancies. BMI is a weight-to-height measure, not a complete account of nutrition or fetal growth. For example, the range for a singleton pregnancy cannot simply be reused for twins. Ask how the team interprets your trend alongside growth assessment, symptoms, intake and medical conditions, and whether nutrition support is needed. Persistent vomiting or difficulty keeping fluids down needs assessment in its own right. A chart does not diagnose the cause of a change or supply a personal meal plan.\n\nImagine someone compares their weight record with a chart and concludes that they must immediately change how much they eat. Before using that chart, the care team needs to know which pregnancy it describes, the starting information and the pattern over time. A singleton chart and a twin chart answer different questions; one isolated number cannot explain a change.\n\nThe person brings the record, symptoms and any difficulty eating or keeping fluids down, then asks how the team interprets them together. The useful outcome is an explained follow-up plan, including whether nutrition or other assessment is needed—not a self-assigned restriction based on a graph. This invented conversation illustrates how to use guidance as a discussion aid. It does not set a personal weight target, diagnose growth or replace prompt assessment of warning symptoms.", "source_ids": [ "weight", "warning-signs" ] }, { "label": "Ask how the care setting responds when needs change", "text": "Risk-appropriate care means matching medical needs to the clinicians, equipment and specialist support available. CDC's levels-of-care work explains why someone with complex disease may need a facility with resources beyond routine care. Midwifery and obstetric services can work together, but a professional title or a preferred experience does not establish a setting's emergency capability. Ask who recognizes a new complication, what specialist support is available, and where and how transfer occurs if more intensive care is needed. Maternal and newborn resources both matter. This makes the backup arrangement understandable without assuming that all pregnancies need the same facility or that all settings offer equivalent support.", "source_ids": [ "care-setting", "midwifery" ] }, { "label": "Bring a previous preterm birth into the current evidence discussion", "text": "Preterm birth means birth before 37 completed weeks. A previous spontaneous preterm birth can change assessment, but an old treatment name is not enough to identify today's options. FDA withdrew 17-OHPC in April 2023 because effectiveness for preventing recurrent spontaneous preterm birth was not established; SMFM's statement, reaffirmed 2025, discourages continued prescribing including compounded versions. Vaginal progesterone for a short cervix and cerclage—a stitch placed in the cervix for selected indications—are separate clinical questions. SMFM also describes uncertainty about progesterone in some other histories. Bring prior records and ask what your current history and cervical assessment support. Do not treat every progesterone formulation, cervical finding or pregnancy type as interchangeable.", "source_ids": [ "preterm" ] }, { "label": "Tell the team what makes appointments hard to use", "text": "Work hours, transportation, childcare, housing, cost, language and technology access can affect whether a care plan is workable. Peahl's care-delivery work and Howell's maternal-health programs address these as service-design and access concerns. A missed appointment is not an explanation of a person's character or a signal that care is no longer worthwhile. Tell the team what is getting in the way and ask about the appropriate practical help, interpretation, coordinated testing or different contact arrangements. If a result is unclear or a symptom concern is dismissed, ask for a plain explanation and the next available clinical assessment. Safety depends on an understandable response as well as a booked visit.", "source_ids": [ "care-preferences", "equity", "prenatal-care" ] } ] }, { "id": "getting-help-between-visits", "role": "cautions", "title": "When to get help between appointments", "intro": "Scheduled care is only one part of the plan. A new warning sign needs a response even after a reassuring test.", "items": [ { "label": "Get prompt clinical help for a warning sign", "text": "CDC's list includes severe or persistent headache, vision change, chest pain, trouble breathing, severe belly pain, fever, fainting, bleeding beyond spotting or fluid leakage, and movement stopping or slowing. If one occurs, seek medical care immediately and use emergency services for an emergency; do not wait for a routine visit or an online response. Once you know your baby's usual movement, a reduction matters—CDC does not give one number that is normal for every pregnancy. Discuss any bleeding with the team and seek urgent care for concerning bleeding or accompanying symptoms. These examples are not an exhaustive rule-out list. If something feels wrong or you are unsure, contact a clinician and say you are pregnant.", "source_ids": [ "warning-signs" ] }, { "label": "Keep follow-up care in place after delivery", "text": "Pregnancy-related problems can arise after birth, so delivery does not end the need for clinical follow-up. CDC's HEAR HER guidance extends into the year after pregnancy and asks patients to tell receiving clinicians about a recent pregnancy. Keep the discharge instructions, urgent contact and handoff for ongoing conditions and medicines together. For instance, a glucose or blood-pressure concern may require follow-up beyond the birth admission; ask which clinician will review it. Stuebe's fourth trimester work treats recovery and support as a continuing care period. Postpartum means after birth, and care in that period concerns the parent's health as well as the infant's.", "source_ids": [ "warning-signs", "panel-9", "equity" ] }, { "label": "Use this reading alongside your own prenatal care", "text": "This is a reading companion, not prenatal care, not a birth plan, and not an intimacy guide. Bleeding, severe headache, vision change, chest pain, or a later drop in fetal movement needs urgent clinical care. Do not start or stop medicines from this text. This page does not treat one pregnancy.\n\nNamed sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.", "source_ids": [ "warning-signs", "medicines" ] } ] }, { "id": "keeping-the-plan-clear", "role": "application", "title": "What to keep with your care record", "intro": "A few useful records help the team review changes without relying on memory. They support the care relationship; they are not a home diagnosis system.", "items": [ { "label": "Know who will explain results and arrange follow-up", "text": "Record who ordered each test and who will explain it, especially if more than one practice is involved. Ask when results are expected and whom to contact if that date passes. A portal notification can show that a result exists without showing that its meaning or next action has been discussed. Bring unanswered questions to the next contact and ask how missed visits are rescheduled.", "source_ids": [ "prenatal-care", "gdm" ] }, { "label": "Keep the agreed supplement plan with the medicine list", "text": "Write the product, ingredient amount and frequency, then add any change the clinical team recommends. This helps avoid accidental overlap when someone suggests another prenatal product. Keep the purpose clear: folic acid lowers the risk of specific early structural defects; it does not treat a detected defect. Review changes rather than interpreting a different bottle as a stronger prevention plan.", "source_ids": [ "folic-label", "folic-acid", "medicines" ] }, { "label": "Keep vaccine dates as well as names", "text": "Record the administered product and date, and bring that record when a different clinic gives care. A list saying flu or RSV does not show whether the intended seasonal or maternal dose was given. Pregnancy week, season and previous receipt can change the answer. Ask the prenatal team to identify what is complete and what still needs a scheduled discussion.", "source_ids": [ "vaccines", "acog-vaccines" ] }, { "label": "Keep urgent instructions where a support person can find them", "text": "Save the after-hours contact and intended care location alongside the warning-sign reminder. A support person can help describe the change or arrange transport, but their reassurance cannot replace an assessment. Ask what to do if the urgent number is unanswered. For an emergency, use emergency services rather than waiting indefinitely for a routine callback.", "source_ids": [ "warning-signs" ] }, { "label": "Keep changes and questions visible between appointments", "text": "Note a new symptom, medicine change or difficulty following the plan so it can be discussed accurately. Record what the team told you and what remains unresolved, rather than collecting an unstructured pile of reassuring screenshots. Routine questions can go through the agreed channel; warning signs need the urgent route. The distinction helps a care team give the right response at the right time.", "source_ids": [ "medicines", "prenatal-care", "warning-signs" ] } ] }, { "id": "checking-common-claims", "role": "findings", "title": "Check the claim before acting on it", "intro": "These answers distinguish evidence from popular reassurance. The verdict concerns the statement shown, not an individual pregnancy.", "items": [ { "label": "Begin the care relationship while you feel well", "text": "Claim: Early prenatal care is the field's starting step. Verdict: established. Early contact begins assessment, prevention and planning; the actual visit schedule can be tailored.", "source_ids": [ "who-care", "prenatal-care" ] }, { "label": "Use folic acid for its specific prevention benefit", "text": "Claim: Folic acid is recommended to prevent neural-tube defects for people who could become pregnant. Verdict: established. The standard recommendation is for average-risk people; higher-risk histories need separate clinical review.", "source_ids": [ "folic-acid", "folic-clinical" ] }, { "label": "Use a product-specific vaccine recommendation", "text": "Claim: Vaccines are never used in pregnancy. Verdict: not what the research found. Guidance recommends specific products with pregnancy-specific timing.", "source_ids": [ "vaccines", "acog-vaccines" ] }, { "label": "Use prevention guidance instead of an anecdotal alcohol allowance", "text": "Claim: A little alcohol in pregnancy has a known safe amount. Verdict: not what the research found. CDC identifies no known safe allowance; past exposure cannot establish an individual prognosis.", "source_ids": [ "alcohol" ] }, { "label": "Let symptoms trigger assessment rather than calendar waiting", "text": "Claim: Severe headache with vision change can wait for the next scheduled visit. Verdict: not what the research found. Those symptoms need urgent clinical assessment.", "source_ids": [ "warning-signs" ] }, { "label": "Know the role of ordinary glucose screening", "text": "Claim: Gestational-diabetes screening is ordinary prenatal care in most US pathways. Verdict: established. USPSTF supports screening at 24 weeks or later; a testing-pathway debate does not remove that recommendation.", "source_ids": [ "gdm", "gdm-pathways" ] }, { "label": "Reserve aspirin for a clinical prevention decision", "text": "Claim: Low-dose aspirin is a general pregnancy vitamin. Verdict: not what the research found. It is a medicine prescribed for selected preeclampsia-risk profiles.", "source_ids": [ "aspirin" ] } ] }, { "id": "one-useful-next-step", "role": "next_steps", "title": "Make the next prenatal contact useful", "intro": "One move: contact the prenatal service, or use your existing team, to confirm the care plan and how you will receive results. Bring the relevant records; use urgent care immediately if a warning sign is present.", "items": [ { "label": "Bring the details that let the team answer your real questions", "text": "Prepare a current medicine and supplement list with doses, product labels, vaccination dates and relevant previous pregnancy records. Ask: What needs attention before my next appointment, which tests come next, and who explains the results? Include the folic-acid question and any access difficulty. This gives the team concrete information to review instead of expecting you to know which history matters.", "source_ids": [ "medicines", "folic-label", "prenatal-care" ] }, { "label": "Try a label-and-record check before the appointment", "text": "Read the folic-acid amount on your actual product and note other vitamins or herbal ingredients you use. Then check your vaccination record for names and dates. Bring uncertainties to the team rather than adding products or repeating doses yourself. The goal is one understandable prevention plan with individual exceptions reviewed by a clinician.", "source_ids": [ "folic-label", "medicines", "vaccines" ] }, { "label": "Try saving the follow-up and urgent routes together", "text": "Ask which number handles routine questions, which route is available after hours and where urgent symptoms should be assessed. Save the instructions where you and a support person can find them. Ask when to expect a test result and what to do if nobody explains it. The plan should cover both ordinary follow-up and unexpected change, including the handoff after delivery.", "source_ids": [ "prenatal-care", "warning-signs" ] } ] } ], "related": [ "nutrition", "sleep", "fitness" ] }, "sources": [ { "id": "prenatal-care", "title": "Revolutionizing prenatal care: new guidelines to transform 100-year model", "url": "https://ihpi.umich.edu/news-events/news/revolutionizing-prenatal-care-new-guidelines-transform-100-year-model", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Opened Michigan's April 2025 account of its work with ACOG: early risk assessment; individualized services, visit schedules, telemedicine and social support.", "limitations": "An institutional explanation from the researchers involved; the full ACOG Clinical Consensus was unavailable for review. It does not establish one visit count for every pregnancy." }, { "id": "care-preferences", "title": "Right-sizing prenatal care", "url": "https://ihpi.umich.edu/news-events/news/right-sizing-prenatal-care", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Peahl's public explanation of a 300-person postpartum preference study, between-visit contact and practical access barriers.", "limitations": "2020 institutional account; preferences do not demonstrate clinical safety or determine any patient's schedule." }, { "id": "who-care", "title": "WHO recommendations on antenatal care for a positive pregnancy experience", "url": "https://www.who.int/publications/i/item/9789241549912", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened overview: assessment, prevention, nutrition, symptoms and person-centred antenatal care; WHO lists subsequent targeted updates.", "limitations": "Publication overview and update links read, not all 196 pages. Global guidance requires local adaptation." }, { "id": "folic-acid", "title": "Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication", "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "2023 USPSTF average-risk recommendation, 400–800 mcg daily, preconception timing, early neural-tube closure, exclusions for very-high-risk histories.", "limitations": "Prevention reduces risk; does not guarantee outcome or treat an established defect; higher-risk dosing requires individual care." }, { "id": "folic-label", "title": "Folic Acid: Sources and Recommended Intake", "url": "https://www.cdc.gov/folic-acid/about/intake-and-sources.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened CDC intake guidance and supplement/food distinction; actual folic-acid amount matters.", "limitations": "General public guidance, not personalized total nutrient requirements or a product endorsement." }, { "id": "folic-clinical", "title": "Folic Acid: Facts for Clinicians", "url": "https://www.cdc.gov/folic-acid/hcp/clinical-overview/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened CDC clinical summary of folic-acid prevention and research on folate forms.", "limitations": "Does not establish that an arbitrary prenatal brand or higher dose is necessary." }, { "id": "mthfr", "title": "MTHFR Gene Variant and Folic Acid Facts", "url": "https://www.cdc.gov/folic-acid/data-research/mthfr/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened CDC explanation that common MTHFR variants do not prevent folic-acid processing and folic acid has neural-tube-prevention evidence.", "limitations": "Common variants are different from rare metabolic disorders; not a personalized genetics assessment." }, { "id": "vaccines", "title": "Guidelines for Vaccinating Pregnant Women", "url": "https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened product/timing table and sections: Tdap each pregnancy, seasonal IIV/RIV, maternal Abrysvo weeks 32–36 and seasonal eligibility, prior maternal RSV receipt.", "limitations": "Page's COVID table is incomplete and linked to later guidance. Maternal RSV rules differ from other adult RSV products; local seasonality matters." }, { "id": "acog-vaccines", "title": "ACOG 2026 Maternal Immunization Schedule", "url": "https://cdn.ymaws.com/npwh.org/resource/resmgr/resources/ACOG_2026_Maternal_Immunizat.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened ACOG schedule hosted by endorsing NPWH; pages 1–2 text: Tdap, COVID-19, influenza and RSV recommendations and timing.", "limitations": "An ACOG schedule hosted by the endorsing organization NPWH, rather than a personal prescription." }, { "id": "covid-current", "title": "Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States", "url": "https://www.cdc.gov/covid/hcp/vaccine-considerations/index.html", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened September 23, 2026 clinical page: 2026–2027 adult recommendation, current regulatory information and individualized benefits/risks discussion.", "limitations": "Landing-page summary read; no brand, dose or regulatory eligibility inferred. A stale 'last updated 2025' subheading conflicts with 2026 page metadata." }, { "id": "covid-pregnancy", "title": "COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding", "url": "https://www.cdc.gov/covid/vaccines/pregnant-or-breastfeeding.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened pregnancy risk/safety explanation and notice directing readers to newer 2026–2027 guidance.", "limitations": "Body still describes 2025–2026 decision language; used for pregnancy risk and update warning, not current schedule." }, { "id": "alcohol", "title": "About Alcohol Use During Pregnancy", "url": "https://www.cdc.gov/alcohol-pregnancy/about/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened current CDC page: no known safe amount/time/type, variable outcomes, prevention after pregnancy recognition and continued checkups.", "limitations": "Cannot predict an individual outcome from a reported exposure." }, { "id": "medicines", "title": "Medicine and Pregnancy: An Overview", "url": "https://www.cdc.gov/medicine-and-pregnancy/about/", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened CDC advice to review prescriptions, OTC medicines, herbal/dietary supplements and vitamins before starting/stopping; untreated illness can also harm.", "limitations": "Many medicines lack adequate pregnancy safety evidence; no medicine-specific approval inferred." }, { "id": "warning-signs", "title": "Urgent Maternal Warning Signs and Symptoms", "url": "https://www.cdc.gov/hearher/maternal-warning-signs/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened CDC warning list, immediate-care direction, pregnancy/recent-pregnancy disclosure, movement change rather than universal count and one-year window.", "limitations": "The list is not exhaustive and cannot diagnose or rule out danger. CDC specifies bleeding beyond spotting; any bleeding should still be discussed with the care team." }, { "id": "gdm", "title": "Gestational Diabetes: Screening", "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-screening", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened USPSTF 2021 summary, implementation and evidence: asymptomatic screening at 24 weeks or later, often 24–28; one-/two-step pathways; earlier evidence insufficient.", "limitations": "Excludes previously diagnosed type 1/2 diabetes; early insufficiency is a dated evidence assessment, not a prohibition and not evaluation of symptoms." }, { "id": "gdm-pathways", "title": "A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9041326/", "kind": "study", "accessed_at": "2026-10-01", "supports": "Opened Hillier et al. 2021 full author manuscript: 23,792 randomized pregnancies, diagnosis 16.5% vs 8.5%, no significant main outcome differences; adherence 66% vs 92%.", "limitations": "Two US integrated systems; nonadherence and threshold differences limit extrapolation. Compares two screened groups, not screening versus no screening." }, { "id": "early-gdm", "title": "Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy", "url": "https://pubmed.ncbi.nlm.nih.gov/37144983/", "kind": "study", "accessed_at": "2026-10-01", "supports": "Opened Simmons et al. 2023 primary-trial abstract: 802 selected women with risk factor and early GDM; neonatal composite 24.9% vs 30.5%; no material hypertension/lean-body-mass differences.", "limitations": "Abstract only; treatment trial in an already selected/diagnosed group, not universal early-screening trial; composite not every component separately." }, { "id": "blood-pressure", "title": "High Blood Pressure During Pregnancy", "url": "https://www.cdc.gov/high-blood-pressure/about/high-blood-pressure-during-pregnancy.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened definitions and prenatal/postpartum blood-pressure significance, preeclampsia and related clinical features.", "limitations": "General education; no home diagnostic threshold or treatment algorithm supplied." }, { "id": "aspirin", "title": "Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication", "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened USPSTF 2021 recommendation/risk factors and evidence: 81 mg/day after 12 weeks for selected high-risk pregnancies; pooled preeclampsia RR 0.85.", "limitations": "Clinician prescribing, not universal supplement advice. Absolute benefit varies with baseline risk; prevention does not rule out later symptoms." }, { "id": "genetic-screening", "title": "Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance", "url": "https://publications.smfm.org/publications/620-society-for-maternal-fetal-medicine-consult-series-74cell/", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened SMFM 2025 summary endorsed by ACOG: common aneuploidy screening, informed accept/decline choice, opt-in sex-chromosome screening and no routine microdeletion screening.", "limitations": "Screening does not diagnose; recommendation varies by target condition, pregnancy type and test method." }, { "id": "genetic-detail", "title": "SMFM Consult Series #74 full guidance", "url": "https://assets.noviams.com/novi-file-uploads/smfm/Publications_and_Guidelines/Consults/SMFM_Consult_Series_74_Cell_free_DNA_screening_for_aneuploidies_Updated_guidance.pdf", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened PDF relevant sections on placental DNA, false results, pretest counseling, confirmatory testing and CVS/amniocentesis tradeoffs for sex-chromosome results.", "limitations": "Relevant sections read, not every reference or full 25 pages line by line. Rare conditions have limited confirmation data; not a personal test decision." }, { "id": "weight", "title": "Weight Gain During Pregnancy", "url": "https://www.cdc.gov/maternal-infant-health/pregnancy-weight/index.html", "kind": "official", "accessed_at": "2026-10-01", "supports": "Explains BMI-specific ranges for singleton and twin pregnancies and the role of discussion with the care team.", "limitations": "Population ranges are not individual diagnosis, diet plan or moral judgment. No target range assigned to reader." }, { "id": "care-setting", "title": "CDC Levels of Care Assessment Tool (CDC LOCATe)", "url": "https://www.cdc.gov/maternal-infant-health/php/cdc-locate/", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened risk-appropriate facility care, specialist/equipment availability and variable state definitions; based on ACOG/SMFM/AAP guidance.", "limitations": "Public-health tool, not certification of any specific hospital or home/birth-centre setting." }, { "id": "preterm", "title": "SMFM Statement: Response to FDA withdrawal of 17-alpha hydroxyprogesterone caproate", "url": "https://publications.smfm.org/publications/467-society-for-maternal-fetal-medicine-statement-response-to/", "kind": "guideline", "accessed_at": "2026-10-01", "supports": "Opened 2023 statement reaffirmed 2025: April 5, 2023 withdrawal, discourage compounded 17-OHPC; distinct short-cervix progesterone/cerclage indications and shared-decision uncertainty remain.", "limitations": "Does not establish a prevention regimen for all prior preterm births or all pregnancy types." }, { "id": "midwifery", "title": "Midwifery — University of Maryland School of Medicine", "url": "https://www.medschool.umaryland.edu/ob/divisions--centers/midwifery/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Opened official patient explanation of CNM/physician teamwork, prenatal care, postpartum and nutrition education; Fahey named.", "limitations": "One service model; not proof all midwifery or obstetric settings have equivalent resources." }, { "id": "equity", "title": "New center will tackle racial disparities in maternal health", "url": "https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Opened Howell-led program account: care access, treatment standardization and postpartum coordination.", "limitations": "Institutional description of programs/research plans; does not prove every proposed program improves every outcome." }, { "id": "question-first-visit", "title": "Early pregnancy — public discussion", "url": "https://www.reddit.com/r/pregnant/comments/1vqomr6/early_pregnancy/", "kind": "question_signal", "accessed_at": "2026-10-01", "supports": "Opened reader's question about an appointment a month away, folic acid and medicines; used to choose reader situations.", "limitations": "Anonymous self-report and comments are not factual authority, clinical advice or representative prevalence." }, { "id": "question-weight", "title": "Any experiences with not gaining a lot of weight during twin pregnancy?", "url": "https://www.reddit.com/r/parentsofmultiples/comments/1tdisyt/any_experiences_with_not_gaining_a_lot_of_weight/", "kind": "question_signal", "accessed_at": "2026-10-01", "supports": "Opened worry about generic twin weight-gain ranges; informs nonjudgmental explanation.", "limitations": "Anecdotes cannot establish a safe weight target or fetal growth assessment." }, { "id": "panel-1", "title": "Catherine Y. Spong — official role and public contribution", "url": "https://utswmed.org/doctors/catherine-spong/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor; Official public biography explains fetal-complication research and inclusion of pregnant people in studies.", "limitations": "Role/publication biography does not establish every treatment claim or offer individual prenatal care." }, { "id": "panel-2", "title": "Mary E. D'Alton — official role and public contribution", "url": "https://www.obgyn.columbia.edu/profile/mary-e-dalton-md", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor; Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.", "limitations": "Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding." }, { "id": "panel-3", "title": "Uma M. Reddy — official role and public contribution", "url": "https://medicine.yale.edu/profile/uma-reddy/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor; Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.", "limitations": "Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current." }, { "id": "panel-4", "title": "Dwight J. Rouse — official role and public contribution", "url": "https://www.brownhealth.org/providers/dwight-j-rouse-md", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health; Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.", "limitations": "CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately." }, { "id": "panel-5", "title": "George R. Saade — official role and public contribution", "url": "https://www.odu.edu/directory/profiles/george-saade", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor; Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.", "limitations": "Professional leadership is not individual prognosis; no article claim rests solely on his role." }, { "id": "panel-6", "title": "Vincenzo Berghella — official role and public contribution", "url": "https://profiles.jefferson.edu/display/32938", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor; Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.", "limitations": "Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance." }, { "id": "panel-7", "title": "Jeanne S. Sheffield — official role and public contribution", "url": "https://profiles.hopkinsmedicine.org/provider/jeanne-s-sheffield/2700629", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director; Official patient biography explicitly explains infectious-disease and immunization expertise.", "limitations": "Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing." }, { "id": "panel-8", "title": "Laura E. Riley — official role and public contribution", "url": "https://weillcornell.org/laura-e-riley-md", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; maternal-fetal medicine specialist at Weill Cornell Medicine; Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.", "limitations": "Leadership and public reach do not replace vaccine safety data or product-specific recommendations." }, { "id": "panel-9", "title": "Alison M. Stuebe — official role and public contribution", "url": "https://news.unchealthcare.org/2020/10/stuebe-named-maternal-fetal-medicine-division-director/", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher; Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.", "limitations": "2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions." }, { "id": "panel-10", "title": "Aaron B. Caughey — official role and public contribution", "url": "https://www.ohsu.edu/people/aaron-b-caughey-md-phd", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound; Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.", "limitations": "No claim that this profile establishes a universal delivery date or personal screening plan." }, { "id": "panel-11", "title": "Alex F. Peahl — official role and public contribution", "url": "https://medschool.umich.edu/profile/5667/alex-f-peahl", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MSc; University of Michigan assistant professor of obstetrics/gynecology; Opened public interviews about tailored prenatal care and official clinical/research profile.", "limitations": "Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies." }, { "id": "panel-12", "title": "Mary E. Norton — official role and public contribution", "url": "https://profiles.ucsf.edu/mary.norton", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD; UCSF perinatologist and clinical geneticist; Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.", "limitations": "Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant." }, { "id": "panel-13", "title": "Wanda K. Nicholson — official role and public contribution", "url": "https://publichealth.gwu.edu/departments/prevention-and-community-health/wanda-nicholson", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor; Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.", "limitations": "USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader." }, { "id": "panel-14", "title": "Jenifer O. Fahey — official role and public contribution", "url": "https://www.umms.org/find-a-doctor/profiles/jenifer-fahey-1538197017", "kind": "professional", "accessed_at": "2026-10-01", "supports": "CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician; Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.", "limitations": "Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives." }, { "id": "panel-15", "title": "Elizabeth A. Howell — official role and public contribution", "url": "https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health", "kind": "professional", "accessed_at": "2026-10-01", "supports": "MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader; Opened public institutional explanations of maternal-health equity and continued care after pregnancy.", "limitations": "A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities." }, { "id": "rouse-teaching", "title": "Dwight J. Rouse curriculum vitae (September 2019)", "url": "https://vivo.brown.edu/docs/d/drouse_cv.pdf?dt=515610267", "kind": "professional", "accessed_at": "2026-10-01", "supports": "Opened historical credentials, teaching awards and guideline/evidence review contributions.", "limitations": "Historical CV; no current administrative position inferred." }, { "id": "fahey-teaching", "title": "Maryland Midwives Workgroup Meeting 4 minutes (December 3, 2012)", "url": "https://health.maryland.gov/midwives/Documents/MidwivesWorkgroupMeeting4-Minutes12-3-12.pdf", "kind": "official", "accessed_at": "2026-10-01", "supports": "Opened public minutes recording Fahey's hospital-based midwifery presentation.", "limitations": "Historical professional public education, not current regulation or clinical outcome evidence." } ], "professional_panel": [ { "name": "Catherine Y. Spong", "credential": "MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor", "official_url": "https://utswmed.org/doctors/catherine-spong/", "public_usefulness": "Official public biography explains fetal-complication research and inclusion of pregnant people in studies.", "contribution": "Connects prenatal evidence literacy to the populations actually studied, rather than assuming every pregnancy is represented.", "boundary": "Role/publication biography does not establish every treatment claim or offer individual prenatal care.", "reviewed_at": "2026-10-01" }, { "name": "Mary E. D'Alton", "credential": "MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor", "official_url": "https://www.obgyn.columbia.edu/profile/mary-e-dalton-md", "public_usefulness": "Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.", "contribution": "Explains why staff, specialist access and referral capability matter for high-risk care.", "boundary": "Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding.", "reviewed_at": "2026-10-01" }, { "name": "Uma M. Reddy", "credential": "MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor", "official_url": "https://medicine.yale.edu/profile/uma-reddy/", "public_usefulness": "Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.", "contribution": "Shows how pregnancy history changes monitoring and why a screening result cannot replace continuing care.", "boundary": "Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current.", "reviewed_at": "2026-10-01" }, { "name": "Dwight J. Rouse", "credential": "MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health", "official_url": "https://www.brownhealth.org/providers/dwight-j-rouse-md", "public_usefulness": "Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.", "contribution": "Provides an evidence-method perspective: clinical trial populations/comparators matter more than a familiar protocol.", "boundary": "CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately.", "reviewed_at": "2026-10-01" }, { "name": "George R. Saade", "credential": "MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor", "official_url": "https://www.odu.edu/directory/profiles/george-saade", "public_usefulness": "Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.", "contribution": "Helps contextualize high-risk pregnancy trials and how evidence becomes professional guidance.", "boundary": "Professional leadership is not individual prognosis; no article claim rests solely on his role.", "reviewed_at": "2026-10-01" }, { "name": "Vincenzo Berghella", "credential": "MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor", "official_url": "https://profiles.jefferson.edu/display/32938", "public_usefulness": "Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.", "contribution": "Preterm prevention and evidence synthesis support explaining why different progesterone formulations/indications are not interchangeable.", "boundary": "Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance.", "reviewed_at": "2026-10-01" }, { "name": "Jeanne S. Sheffield", "credential": "MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director", "official_url": "https://profiles.hopkinsmedicine.org/provider/jeanne-s-sheffield/2700629", "public_usefulness": "Official patient biography explicitly explains infectious-disease and immunization expertise.", "contribution": "Adds pregnancy-specific infection and vaccine interpretation rather than a blanket vaccine rule.", "boundary": "Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing.", "reviewed_at": "2026-10-01" }, { "name": "Laura E. Riley", "credential": "MD; maternal-fetal medicine specialist at Weill Cornell Medicine", "official_url": "https://weillcornell.org/laura-e-riley-md", "public_usefulness": "Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.", "contribution": "Connects infection prevention to clinical pregnancy care and public explanation of immunization questions.", "boundary": "Leadership and public reach do not replace vaccine safety data or product-specific recommendations.", "reviewed_at": "2026-10-01" }, { "name": "Alison M. Stuebe", "credential": "MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher", "official_url": "https://news.unchealthcare.org/2020/10/stuebe-named-maternal-fetal-medicine-division-director/", "public_usefulness": "Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.", "contribution": "Preserves the handoff from pregnancy to recovery, ongoing conditions and postpartum support.", "boundary": "2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions.", "reviewed_at": "2026-10-01" }, { "name": "Aaron B. Caughey", "credential": "MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound", "official_url": "https://www.ohsu.edu/people/aaron-b-caughey-md-phd", "public_usefulness": "Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.", "contribution": "Adds a clinical-research/policy perspective on prenatal screening choices and outcome comparisons.", "boundary": "No claim that this profile establishes a universal delivery date or personal screening plan.", "reviewed_at": "2026-10-01" }, { "name": "Alex F. Peahl", "credential": "MD, MSc; University of Michigan assistant professor of obstetrics/gynecology", "official_url": "https://medschool.umich.edu/profile/5667/alex-f-peahl", "public_usefulness": "Opened public interviews about tailored prenatal care and official clinical/research profile.", "contribution": "MiPATH research examines how prenatal services can respond to medical risk and practical barriers to care.", "boundary": "Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies.", "reviewed_at": "2026-10-01" }, { "name": "Mary E. Norton", "credential": "MD; UCSF perinatologist and clinical geneticist", "official_url": "https://profiles.ucsf.edu/mary.norton", "public_usefulness": "Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.", "contribution": "Clarifies the distinct jobs of a screening estimate and diagnostic confirmation.", "boundary": "Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant.", "reviewed_at": "2026-10-01" }, { "name": "Wanda K. Nicholson", "credential": "MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor", "official_url": "https://publichealth.gwu.edu/departments/prevention-and-community-health/wanda-nicholson", "public_usefulness": "Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.", "contribution": "Explains how to evaluate prevention evidence and maintain care from pregnancy through the postpartum period.", "boundary": "USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader.", "reviewed_at": "2026-10-01" }, { "name": "Jenifer O. Fahey", "credential": "CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician", "official_url": "https://www.umms.org/find-a-doctor/profiles/jenifer-fahey-1538197017", "public_usefulness": "Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.", "contribution": "Explains collaborative midwifery care, informed choices and nutrition education.", "boundary": "Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives.", "reviewed_at": "2026-10-01" }, { "name": "Elizabeth A. Howell", "credential": "MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader", "official_url": "https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health", "public_usefulness": "Opened public institutional explanations of maternal-health equity and continued care after pregnancy.", "contribution": "Her work examines how access, communication and coordination among services affect maternal care.", "boundary": "A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities.", "reviewed_at": "2026-10-01" } ] }